News

Final Judgment Entered in Kurin’s Favor over Magnolia Medical

June 18, 2024

Kurin Announces Appointment of Chief Commercial Officer

May 30, 2024

Court Determines that Kurin Does Not Infringe Magnolia Medical Patent

May 16, 2024

Kurin, Inc. Reports Record Revenue for Q1 2024

April 3, 2024

Kurin, Inc. Files False Advertising Lawsuit Against ICU Medical and Vascular Integrity

March 28, 2024

USPTO Examiner Affirms Rejection of Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

March 6, 2024

USPTO Issues Final Rejection of Magnolia Medical’s ‘483 Patent at Issue in Litigation

December 6, 2023

Kurin, Inc. Reports Record Revenue for Q3 2023

October 5, 2023

Kurin, Inc. Named 2023 Diverse Supplier of the Year by Vizient

September 27, 2023

USPTO Rejects Patent Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

August 15, 2023

Delaware Federal Court Issues a Stay Order in Patent Dispute between Magnolia Medical and Kurin, Inc.

August 10, 2023

Kurin Launches Kurin Jet, Redefining the Blood Culture Contamination Device Market

July 12, 2023

USPTO Agrees to Kurin’s Request to Review Validity of Magnolia Medical’s ‘483 Patent

May 3, 2023

Kurin Receives 510k from the FDA with Indication to Reduce Blood Culture Contaminations

May 2, 2023

Kurin Commends the CDC for Their Recent Publication on Blood Culture Contamination

March 14, 2023

ENA Welcomes Kurin to 2023 Corporate Engagement Council

March 8, 2023

Kurin Announces Kurin Jet, A Quantum Leap Forward in Devices Designed to Address Blood Culture Contamination

February 15, 2023

Kurin, Inc. Reports Record Revenue for 2022

January 26, 2023

Kurin, Inc. Announces Successful FDA Audit

September 28, 2022

Kurin, Inc. Provides Update on Litigation Activity

September 15, 2022
1 2 3

ML-021 Rev A